Benchmark Industries Inc

New England Horse Labs offers ParaScreen-e, an innovative mail-in fecal collection kit designed to make fecal testing accessible and convenient for horse owners. By identifying equine intestinal parasites and determining fecal egg counts, they assist owners and veterinarians in creating tailored deworming programs specific to individual farms and horses. The company emphasizes the importance of fecal testing in the face of evolving parasitic resistance to conventional drugs, ensuring an effective and targeted approach to parasite control. With laboratory results provided within 24 hours, New England Horse Labs aims to promote better health and management practices in equine care through informed decision-making. Generated from the website

Parklund Orthodontic Lab, located in Millbury, Massachusetts, has been specializing in the fabrication of orthodontic appliances since 1991. With a staff boasting over 100 years of combined experience, the lab emphasizes the production of high-quality appliances with quick turnaround times to serve its clients effectively. The lab offers a diverse range of products including retainers, splints, expanders, and custom mouthguards. Parklund Labs is dedicated to providing exceptional service and quality, striving to build lasting relationships with dental professionals and orthodontists. Generated from the website

Microbiotix is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company has four novel compound series in research and development. Microbiotix developed MBX 500, the first antibiotic that targets the deoxyribonucleic acid polymerase of gram-positive bacteria, including drug resistant strains. The company has an active research program to discover a broad-spectrum antibiotic that targets DNA replication of drug-resistant gram-positive and gram-negative bacteria. In addition to MBX 500, Microbiotix's most advanced antiviral compounds are for the treatment of respiratory syncytial virus (MBX 300) and cytomegalovirus (MBX400) which are in pre-clinical development. It also has an active biodefense program, focused on novel therapeutics for Bacillus Anthraocis and Burkholderia pseudomalli. Based in Worcester, Mass., Microbiotix is involved in the discovery of inhibitors of bacterial biofilm formation and antibiotic resistance.